News

Dermatology Times is counting down to the annual Fall Clinical conference in Las Vegas, Nevada, with our top 5 headlines and highlights from this year's PA and NP summer conference.

Keep up with the latest headlines in dermatology from the past week, including a newly-developed electronic skin, the first ever use of CRISPR technology to explore the genetics of human melanin production, and more.

As awareness of epidermolysis bullosa has grown, companies have increased research into innovative therapies.

ICYMI, this week we had stories about rising derm stars from the World Congress of Dermatology, secukinumab for pediatric patients with plaque psoriasis, remibrutinib for rapid symptom control of urticaria, and more.

Investigators wanted to find a testing option if other parameters are negative or conflicting and LE is suspected.

The Soligenix study is supported by a US Food and Drug Administration Orphan Products Development grant award.

Back-to-school season is an opportunity for dermatology clinicians to empower pediatric, adolescent, and young adult patients with treatment solutions for diagnoses including acne, atopic dermatitis, and skin cancer.

Five nurse practitioners and physician assistants review patient case presentations and discuss unmet needs in the psoriasis landscape.

Genetic variants associated with hidradenitis suppurativa (HS) were identified, although a causal effect is not proven.

In a survey, 99% of aesthetic practitioners and professionals said the product made lips look full and healthy.

The highly selective oral BTK inhibitor is emerging in the treatment landscape as a potential therapeutic option for urticaria uncontrolled by H1-antihistamines.

At 3 months post-treatment, skin texture and laxity showed significant improvement.

The treatments also led to a decrease in the density of immunohistochemistry of sweat glands.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.

Patients given LNK01001 showed significant improvement in EASI scores over placebo.

Research showed that many patients with skin cancer who had been treated using immunotherapy, such as immune checkpoint inhibition, experienced chronic side effects.

Dermatology Times is counting down to the annual fall SDPA conference in Nashville, Tennessee, with our top 10 headlines and highlights from this year's summer conference.

With hormonal fluctuations, constantly changing schedules, and various afterschool activities, addressing the specific needs of teenage skin becomes essential to promote a lifetime of proper skin care practices.

This week’s collection of the latest dermatologic studies covers an evaluation of the human stratum corneum with confocal Raman micro-spectroscopy, anti-mBP180 antibodies from mice, an updated review of alopecia areata comorbidities, and an ecchymotic patch related to chronic lymphocytic leukemia.

A grant from the National Institutes of Health will support continued research to develop products for soft tissue regeneration.

In subgroups based on age and bodyweight, treatment with secukinumab did not create new safety signals.

Researchers conducted systematic mapping of relevant DHI literature to determine the impact of these interventions on dermatologic care outcomes.

The guidance draft, once finalized, will enable the US FDA to have more oversight in the realm of cosmetic safety.

Clinically asymptomatic patients receiving alternative to conventional follow-up had a higher 3-year overall survival rate.

From bug bites to poison ivy, the skin can be exposed to a large spectrum of trouble while patients spend extended time outside.

In this week’s Pointers With Portela, the 208SkinDoc answers frequently asked questions about sunscreen use.

Clinicians can focus on patient care and leave human resources and bookkeeping to office staff.

Studies showed the various treatments improved symptoms, but more trials need to be done.

During the 25th World Congress of Dermatology, 40 rising stars and personalities were spotlighted for their contributions to the field.

This Psoriasis Awareness Month, test your knowledge of the condition. Click here to answer this week's poll.